Drugs / therapeutic tumor infiltrating lymphocytes
therapeutic tumor infiltrating lymphocytes
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT00301730 | Oct 2005 → ? | breast cancer, metastatic malignant neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00085462 | May 2004 → May 2007 | cutaneous melanoma | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1 | NCT00045149 | Oct 2002 → Jun 2005 | cutaneous melanoma | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00019357 | Jun 1998 → ? | cancer of unknown primary site | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00002572 | Nov 1994 → Dec 1999 | central nervous system neoplasm | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00062036 | Jun 2003 → Feb 2007 | cutaneous melanoma | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1/2 | NCT00002786 | Oct 1995 → Mar 2006 | cutaneous melanoma | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT01807182 | Aug 2013 → Aug 2021 | cutaneous melanoma, metastatic melanoma | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00096382 | Sep 2004 → Jan 2009 | cutaneous melanoma | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 2 | NCT00019084 | Feb 1996 → May 2003 | breast cancer, cervical cancer, colorectal cancer, lung cancer +2 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00002733 | Jan 1996 → Jan 2000 | cutaneous melanoma, kidney cancer | Hoag Memorial Hospital Presbyterian | Completed | No outcome recorded |
| Phase 2 | NCT00002535 | Jul 1993 → Jul 2004 | cutaneous melanoma | St. Luke's Medical Center | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT07628894 Background | Dec 2026 → Jul 2027 expected | cutaneous melanoma | City of Hope Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT00003665 Background | Apr 1999 → Oct 2002 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00046852 Background | Dec 2001 → Nov 2004 | infectious disease, plasma cell myeloma | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 2 | NCT02500576 Background | Aug 2015 → Oct 2022 | cutaneous melanoma, metastatic melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | therapeutic tumor infiltrating lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00062036 ↗ |
| Known as | TDTL | “tumor-derived T-lymphocytes (TDTL)” NCT00301730 ↗ |
| Known as | TIL | “NSC-373364 LAK Lymphokine-Activated Killer Cells TIL Tumor Infiltrating Lymphocytes” NCT00002535 ↗1“autologous tumor infiltrating lymphocytes (TIL)” NCT00002733 ↗ |
| Known as | Tumor Infiltrating Lymphocytes | “NSC-373364 LAK Lymphokine-Activated Killer Cells TIL Tumor Infiltrating Lymphocytes” NCT00002535 ↗1“autologous tumor infiltrating lymphocytes (TIL)” NCT00002733 ↗ |
| Known as | tumor-derived T-lymphocytes | “tumor-derived T-lymphocytes (TDTL)” NCT00301730 ↗ |
| Modality | Cell therapy | “IL-2-activated TIL” NCT00002535 ↗ |
| Route | Other | “intracavitary cytotoxic T lymphocytes” NCT00002572 ↗ |